Drug information of Rilonacept

Mechanism of effect

Blocks interleukin-1beta (IL-1beta) signaling by acting as a soluble decoy receptor that binds IL-1beta and prevents its interaction with cell surface receptors

Pharmacodynamic

Treatment with Rilonacept resulted in decreased levels of mean C-Reactive Protein (CRP) and Serum Amyloid A (SAA). Higher levels of CRP and SAA are associated with inflammatory disease activity found in patients with Cryopyrin-Associated Periodic Syndrome

Pharmacokinetics

Half life: 8.6 hours

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Clearance

Not Available

Toxicity

Not Available

Drug indications

Rilonacept (rilonacept systemic) is a member of the drug class interleukin inhibitors and is used to treat Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Gout and Muckle Wells Syndrome.

Dosage

Loading dose: 320 mg SC administered as two 2-mL injections (160 mg each) given on the same day at 2 different injection sites

Maintenance: 160 mg SC qWeek

 

Drug contraindications

None

Side effects

>10%

Injection site reactions (48%)

Infections (34-48%)

Upper respiratory tract infections (26%)

1-10%

Cough (9%)

Sinusitis (9%)

<1%

Hypersensitivity reaction

Neutropenia

Interactions

Thymoglubin , Canakinumab , Basiliximab , Alefacept , Everolimus , Pneumovax , Tacrolimus , Sirolimus , Cyclosporine , Glatiramer acetate , Tocilizumab , Anakinra , Muromonab-CD3 , Hepatitis B Vaccine , Typhoid vaccine (live), oral , Hydroxychloroquine , Human papillomma virus vaccine , Influenza vaccine , Adalimumab , Certolizumab , Golimumab , Meningococcal conjugate vaccine , Rabies Vaccine

• adalimumab
• alefacept
• anakinra
• azathioprine
• baricitinib
• basiliximab
• BCG vaccine live
• canakinumab
• certolizumab pegol
• cyclosporine
• etanercept
• everolimus
• glatiramer
• golimumab
• hepatitis A vaccine inactivated
• hepatitis a/b vaccine
• hepatitis b vaccine
• human papillomavirus vaccine,
• hydroxychloroquine sulfate
• infliximab
• influenza virus vaccine
• leflunomide
• muromonab CD3
• mycophenolate
• pneumococcal vaccine 13-valent
• pneumococcal vaccine heptavalent
• pneumococcal vaccine polyvalent
• sirolimus
• tacrolimus
• temsirolimus
• tetanus toxoid adsorbed or fluid
• tocilizumab
• typhoid vaccine live

Alerts

• Discontinue if patient develops serious infection
• Concomitant TNF-alpha or IL-1 inhibitors not recommended

Pregnancy level

Group c - Not adequate studies in pregnant women